SEARCH

SEARCH BY CITATION

References

  • 1
    Myers, J. D. ( 2009) Growing old with HIV: the AIDS epidemic and an aging population. JAAPA 22, 2024.
  • 2
    Valcour, V., Shikuma, C., Shiramizu, B., Watters, M., Poff, P., et al. ( 2004) Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 63, 822827.
  • 3
    Xu, J. and Ikezu, T. ( 2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J. Neuroimmune Pharm. 4, 200212.
  • 4
    Giometto, B., An, S. F., Groves, M., Scaravilli, T., Geddes, J. F., et al. ( 1997) Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities. Ann. Neurol. 42, 3440.
  • 5
    Esiri, M. M., Biddolph, S. C., and Morris, C. S. ( 1998) Prevalence of Alzheimer plaques in AIDS. J. Neurol. Neurosurg. Psychiatry 65, 2933.
  • 6
    Rempel, H. C. and Pulliam, L. ( 2005) HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19, 127135.
  • 7
    Achim, C. L., Adame, A., Dumaop, W., Everall, I. P., and Masliah, E. ( 2009) Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J. Neuroimmune Pharmacol. 4, 190199.
  • 8
    Aksenov, M. Y., Aksenova, M. V., Mactutus, C. F., and Booze, R. M. ( 2010) HIV-1 protein-mediated amyloidogenesis in rat hippocampal cell cultures. Neurosci. Lett. 475, 174178.
  • 9
    Andras, I. E., Eum, S. Y., Huang, W., Zhong, Y., Hennig, B., et al. ( 2010) HIV-1-induced amyloid beta accumulation in brain endothelial cells is attenuated by simvastatin. Mol. Cell. Neurosci. 43, 232243.
  • 10
    Giunta, B., Hou, H., Zhu, Y., Rrapo, E., Tian, J., et al. ( 2009) HIV-1 Tat contributes to Alzheimer's disease-like pathology in PSAPP mice. Int. J. Clin. Exp. Pathol. 2, 433443.
  • 11
    Zhang, J., Liu, J., Katafiasz, B., Fox, H., and Xiong, H. ( 2011) HIV-1 gp120-induced axonal injury detected by accumulation of beta-amyloid precursor protein in adult rat corpus callosum. J. Neuroimmune Pharmacol. 6, 650657.
  • 12
    Kure, K., Lyman, W. D., Weidenheim, K. M., and Dickson, D. W. ( 1990) Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am. J. Pathol. 136, 10851092.
  • 13
    Koenig, S., Gendelman, H. E., Orenstein, J. M., Dal Canto, M. C., Pezeshkpour, G. H., et al. ( 1986) Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233, 10891093.
  • 14
    Minagar, A., Shapshak, P., Fujimura, R., Ownby, R., Heyes, M., et al. ( 2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J. Neurol. Sci. 202, 1323.
  • 15
    Pulliam, L. ( 2009) HIV regulation of amyloid beta production. J. Neuroimmune Pharmacol. 4, 213217.
  • 16
    Andras, I. E., Rha, G., Huang, W., Eum, S., Couraud, P. O., et al. ( 2008) Simvastatin protects against amyloid beta and HIV-1 Tat-induced promoter activities of inflammatory genes in brain endothelial cells. Mol. Pharmacol. 73, 14241433.
  • 17
    Mattson, M. P., Haughey, N. J., and Nath, A. ( 2005) Cell death in HIV dementia. Cell Death Differ. 12 ( suppl 1), 893904.
  • 18
    Letendre, S., Marquie-Beck, J., Capparelli, E., Best, B., Clifford, D., et al. ( 2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol. 65, 6570.
  • 19
    Giunta, B., Ehrhart, J., Obregon, D. F., Lam, L., Le, L., et al. ( 2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol. Brain 4, 23.
  • 20
    Zlokovic, B. V. ( 2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28, 202208.
  • 21
    Deane, R., Wu, Z., and Zlokovic, B. V. ( 2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 26282631.
  • 22
    Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., et al. ( 2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 14891499.
  • 23
    Sagare, A., Deane, R., Bell, R. D., Johnson, B., Hamm, K., et al. ( 2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13, 10291031.
  • 24
    Pflanzner, T., Janko, M. C., Andre-Dohmen, B., Reuss, S., Weggen, S., et al. ( 2011) LRP1 mediates bidirectional transcytosis of amyloid-beta across the blood-brain barrier. Neurobiol. Aging 32, 2323.e2321–e2311.
  • 25
    Jaeger, L. B., Dohgu, S., Hwang, M. C., Farr, S. A., Murphy, M. P., et al. ( 2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J. Alzheimer Dis. 17, 553570.
  • 26
    Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., et al. ( 2003) RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907913.
  • 27
    Grillo, M. A. and Colombatto, S. ( 2008) Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 35, 2936.
  • 28
    Verdier, Y., Zarandi, M., and Penke, B. ( 2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J. Pept. Sci. 10, 229248.
  • 29
    Sturchler, E., Galichet, A., Weibel, M., Leclerc, E., and Heizmann, C. W. ( 2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J. Neurosci. 28, 51495158.
  • 30
    Zhang, L., Postina, R., and Wang, Y. ( 2009) Ectodomain shedding of the receptor for advanced glycation end products: a novel therapeutic target for Alzheimer's disease. Cell. Mol. Life Sci. 66, 39233935.
  • 31
    Ujiie, M., Dickstein, D. L., Carlow, D. A., and Jefferies, W. A. ( 2003) Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10, 463470.
  • 32
    Andras, I. E., Eum, S. Y., and Toborek, M. ( 2012) Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells. Biochem. Biophys. Res. Commun. 421, 177183.
  • 33
    Nasreddine, N., Borde, C., Gozlan, J., Belec, L., Marechal, V., et al. ( 2011) Advanced glycation end products inhibit both infection and transmission in trans of HIV-1 from monocyte-derived dendritic cells to autologous T cells. J. Immunol. 186, 56875695.
  • 34
    Li, M., Shang, D. S., Zhao, W. D., Tian, L., Li, B., et al. ( 2009) Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 182, 57785788.
  • 35
    Krohn, M., Lange, C., Hofrichter, J., Scheffler, K., Stenzel, J., et al. ( 2011) Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in mice. J. Clin. Invest. 121, 39243931.
  • 36
    Hartz, A. M., Miller, D. S., and Bauer, B. ( 2010) Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol. Pharmacol. 77, 715723.
  • 37
    van Assema, D. M., Lubberink, M., Bauer, M., van der Flier, W. M., Schuit, R. C., et al. ( 2012) Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135, 181189.
  • 38
    Persidsky, Y., Zheng, J., Miller, D., and Gendelman, H. E. ( 2000) Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J. Leukoc. Biol. 68, 413422.
  • 39
    Langford, D., Grigorian, A., Hurford, R., Adame, A., Ellis, R. J., et al. ( 2004) Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J. Neuropathol. Exp. Neurol. 63, 10381047.
  • 40
    Tai, L. M., Loughlin, A. J., Male, D. K., and Romero, I. A. ( 2009) P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J. Cereb. Blood Flow Metab. 29, 10791083.
  • 41
    Xiong, H., Callaghan, D., Jones, A., Bai, J., Rasquinha, I., et al. ( 2009) ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J. Neurosci. 29, 54635475.
  • 42
    Persidsky, Y., Ramirez, S. H., Haorah, J., and Kanmogne, G. D. ( 2006) Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J. Neuroimmune Pharmacol. 1, 223236.
  • 43
    Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., et al. ( 2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41, 10881093.
  • 44
    Bell, R. D., Deane, R., Chow, N., Long, X., Sagare, A., et al. ( 2009) SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 11, 143153.
  • 45
    Zlokovic, B. V., Martel, C. L., Matsubara, E., McComb, J. G., Zheng, G., et al. ( 1996) Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc. Natl. Acad. Sci. USA 93, 42294234.
  • 46
    Baig, S., Palmer, L. E., Owen, M. J., Williams, J., Kehoe, P. G., et al. ( 2012) Clusterin mRNA and protein in Alzheimer's disease. J. Alzheimer Dis. 28, 337344.
  • 47
    Zlokovic, B. V., Deane, R., Sagare A. P., Bell, R. D., and Winkler, E. A. ( 2010) Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J. Neurochem. 115, 10771089.
  • 48
    Silverberg, G. D., Messier, A. A., Miller, M. C., Machan, J. T., Majmudar, S. S., et al. ( 2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J. Neuropathol. Exp. Neurol. 69, 10341043.
  • 49
    Michel, V. and Bakovic, M. ( 2007) Lipid rafts in health and disease. Biol. Cell. 99, 129140.
  • 50
    Yanagisawa, K. ( 2005) GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid. Neuroscientist 11, 250260.
  • 51
    Pernber, Z., Blennow, K., Bogdanovic, N., Mansson, J. E., and Blomqvist, M. ( 2012) Altered distribution of the gangliosides GM1 and GM2 in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 174188.
  • 52
    Saavedra, L., Mohamed, A., Ma, V., Kar, S., and de Chaves, E. P. ( 2007) Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J. Biol. Chem. 282, 3572235732.
  • 53
    Lisanti, M. P., Scherer, P. E., Vidugiriene, J., Tang, Z., Hermanowski-Vosatka, A., et al. ( 1994) Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J. Cell. Biol. 126, 111126.
  • 54
    Reddy, M. A., Li, S. L., Sahar, S., Kim, Y. S., Xu, Z. G., et al. ( 2006) Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells. J. Biol. Chem. 281, 1368513693.
  • 55
    Andras, I. E., Pu, H., Tian, J., Deli, M. A., Nath, A., et al. ( 2005) Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J. Cereb. Blood Flow Metab. 25, 11591170.
  • 56
    Zhong, Y., Smart, E. J., Weksler, B., Couraud, P. O., Hennig, B., et al. ( 2008) Caveolin-1 regulates human immunodeficiency virus-1 Tat-induced alterations of tight junction protein expression via modulation of the Ras signaling. J. Neurosci. 28, 77887796.
  • 57
    Wolburg, H., Noell, S., Wolburg-Buchholz, K., Mack, A., and Fallier-Becker, P. ( 2009) Agrin, aquaporin-4, and astrocyte polarity as an important feature of the blood-brain barrier. Neuroscientist 15, 180193.
  • 58
    Rauch, S. M., Huen, K., Miller, M. C., Chaudry, H., Lau, M., et al. ( 2011) Changes in brain beta-amyloid deposition and aquaporin 4 levels in response to altered agrin expression in mice. J. Neuropathol. Exp. Neurol. 70, 11241137.
  • 59
    Greenwood, J. and Mason, J. C. ( 2007) Statins and the vascular endothelial inflammatory response. Trends Immunol. 28, 8898.
  • 60
    Zlokovic, B. V. ( 2008) New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 5, 409414.
  • 61
    Liu, Y., Studzinski, C., Beckett, T., Murphy, M. P., Klein, R. L., et al. ( 2010) Circulating neprilysin clears brain amyloid. Mol. Cell. Neurosci. 45, 101107.
  • 62
    Tran, H., Robinson, S., Mikhailenko, I., and Strickland, D. K. ( 2003) Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J. Lipid Res. 44, 18591869.